Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history

AIDS

Volumn 28, Issue 1, 2014, Pages 121-127

  Cescon, Angela ^a   Chan, Keith ^a   Raboud, Janet M ^b,c   Burchell, Ann N ^c,d   Forrest, Jamie I ^a   Klein, Marina B ^e   Loutfy, Mona R ^c,f,g   MacHouf, Nima ^h   Montaner, Julio S G ^a,i   Tsoukas, Chris ^e   Hogg, Robert S ^a,j   Cooper, Curtis ^k  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ONTARIO HIV TREATMENT NETWORK   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f WOMEN S COLLEGE HOSPITAL   (Canada)

^g MAPLE LEAF MEDICAL CLINIC   (Canada)

^h Clinique Medicale l'Actuel   (Canada)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j SIMON FRASER UNIVERSITY   (Canada)

^k UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

Canada; Coinfection; Hepatitis C; HIV; Injection drug use

Indexed keywords

ATAZANAVIR; EFAVIRENZ; LOPINAVIR; NEVIRAPINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG USE; FEMALE; FOLLOW UP; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MIXED INFECTION; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; VIRUS LOAD; YOUNG ADULT; CANADA; COINFECTION; COMPLICATION; HEPATITIS C, CHRONIC; HIV INFECTIONS; SUBSTANCE ABUSE;

ADULT; CANADA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COINFECTION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84892172683     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000020     Document Type: Article

References (43)

1. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
2. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349:1294.
3. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377:1198-1209.
4. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
5. Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, Bentata M, et al. Liver-related mortality in human-immunodeficiencyvirus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 study). J Viral Hepat 2007; 14:183-188.
6. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156:271-278.
7. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569.
8. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567.
9. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeciency virus infection. Clin Infect Dis 2001; 33:240-247.
10. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 2005; 41:713-720.
11. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 33:365-372.
12. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
13. Raboud J, Anema A, Su D, Klein MB, Zakaryan A, Swan T, et al. Relationship of chronic hepatitis C infection to rates of AIDSdefining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2012; 13:90-102.
14. Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS 2008; 22:1247-1256.
15. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44 (1 Suppl):S6-S9.
16. Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, et al. Cohort profile: the Canadian HIV-Hepatitis C Co-infection Cohort Study. Int J Epidemiol 2010; 39:1162-1169.
17. Public Health Agency of Canada. Summary: estimates of HIV prevalence and incidence in Canada, 2011. www.phac-aspc. gc.ca/aids-sida/publication/ survreport/estimat2011-eng.php. [Accessed 6 May 2013].
18. Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004; 5:174-179.
19. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, et al. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol 2007; 21 (Suppl C):25C-34C.
20. Palmer AK, Klein MB, Raboud J, Cooper C, Hosein S, Loufty M, et al. Cohort profile: the Canadian Observational Cohort collaboration. Int J Epidemiol 2011; 40:25-32.
21. Lima V, Harrigan R, Montaner JS. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 2009; 51: 3-6.
22. Harrigan R, Sherlock C, Hogg RS, Wynhoven B, Chui C, Swenson L, et al. What should be the primary virological endpoint in clinical trials of ARV efficacy? 18th Conference on Retroviruses and Opportunistic Infections; 2011. Boston, MA, USA. Abstract 661.
23. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21:983-991.
24. Urbanus AT, van de Laar TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, et al. Hepatitis C virus infections among HIVinfected men who have sex with men: an expanding epidemic. AIDS 2009; 23:F1-F7.
25. Jin F, Prestage GP, Matthews G, Zablotska I, Rawstorne P, Kippax SC, et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIVnegative and HIV-positive men in Sydney, Australia. Sex Transm Infect 2010; 86:25-28.
26. Pantalone DW, Hessler DM, Bankoff SM, Shah BJ. Psychosocial correlates of HIV-monoinfection and HIV/HCV-coinfection among men who have sex with men. J Behav Med 2012; 35:520-528.
27. Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis 2012; 55:279-290.
28. Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AB, Panos G, et al. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis 2004; 190:148-155.
29. Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003; 32:522-526.
30. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15:1115-1123.
31. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIVon survival.NEngl JMed 2009; 360:1815-1826.
32. Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011; 25:279-290.
33. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16:1051-1058.
34. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003; 169: 656-661.
35. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27:251-259.
36. Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci 2011; 88:948-952.
37. Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crackcocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr 2009; 50:93-99.
38. Rafie C, Campa A, Smith S, Huffman F, Newman F, Baum MK. Cocaine reduces thymic endocrine function: another mechanism for accelerated HIV disease progression. AIDS 2011; 27:815-822.
39. Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses 2010; 26:511-518.
40. Tyndall MW, McNally M, Lai C, Zhang R, Wood E, Kerr T, et al. Directly observed therapy programmes for antiretroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes. Int J Drug Policy 2007; 18:281-287.
41. Small W, Van Borek N, Fairbairn N, Wood E, Kerr T. Access to health and social services for IDU: the impact of a medically supervised injection facility. Drug Alcohol Rev 2009; 28:341-346.
42. Uhlmann S, Milloy MJ, Kerr T, Zhang R, Guillemi S, Marsh D, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 2010; 105:907-913.
43. Milloy MJ, Kerr T, Buxton J, Rhodes T, Krusi A, Guillemi S, et al. Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 59:393-399.